ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $3.56 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.56, a 12.96% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.09.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $7.36, a 43.47% increase year-over-year.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $5.13.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $4.03, a 13.52% increase from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.55, a 463.49% increase from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.63, a 86.71% decline from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $4.74, a 34.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.56 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $3.56 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $4.03 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $4.03 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $4.09 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $4.09 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $3.55 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $0.63 10-K · filed 2024-03-07 | |||
| 2023-09-30 | $0.55 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | $0.55 10-Q · filed 2023-08-03 | |||
| 2022-12-31 | $4.74 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $4.74 10-Q · filed 2022-11-10 | |||
| 2021-12-31 | $7.29 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $7.29 10-Q · filed 2021-10-28 | |||
| 2021-06-30 | $7.31 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $7.36 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $4.83 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $4.83 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $4.18 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $5.13 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $5.01 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $5.00 10-Q · filed 2019-11-07 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-03-08 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-29 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $0.88 10-K · filed 2017-03-30 | |||
| 2016-09-30 | $0.55 10-Q · filed 2016-11-14 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |